Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug. Click for more ...

Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS ...

Why Is CRBU Stock Falling Today? Caribou Biosciences Falls After Halting CAR-T Programs and Exploring Strategic Alternatives ...

For children with high-risk B-cell acute lymphoblastic leukemia (ALL), replacing part of their intensive chemotherapy with ...

According to the experts, clinicians should consider CAR T-cell therapy for patients with severe autoimmune disease that ...

Obexelimab has been evaluated in nine clinical trials in a total of 667 subjects, including MoonStone. Obexelimab was well tolerated and demonstrated clinical activity across these clinical trials.

Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality ...

A two-round expert elicitation among German and Austrian hematologists has produced a consensus list of prognostic factors ...

A new case report documents 127 days of persistent SARS-CoV-2 RNA positivity in a woman with chronic lymphocytic leukaemia, ...

Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value. Caribou Biosciences, Inc. announced that it is exploring ...

大家好啊，节后第一个交易日，创业板就跪了，ai硬件的下跌空间进一步打开了，生物医药这边由于我们昨天的说的，艾力斯伏美替尼美国三期临床失败，今天直接20cm跌停，也带动整个生物医药低迷。

这赋予了mRNA极其广阔的平台拓展空间:只要切换写入的碱基序列,它就能在体内打造出功能各异的“蛋白质工厂”——写入新抗原是肿瘤疫苗,写入TCE是自免利器,未来写入细胞因子、缺失的酶或转录因子,更有望跨越罕见病与代谢疾病等传统药物的盲区。